Get the Stockscreener App
119.28
1.30%
-1.57
Pre-market:
120.82
1.54
+1.29%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $119.28, with a volume of 11.30M.
It is down -1.30% in the last 24 hours and up +3.01% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$120.85
Open:
$119.56
24h Volume:
11.30M
Relative Volume:
0.97
Market Cap:
$294.91B
Revenue:
$64.93B
Net Income/Loss:
$18.26B
P/E Ratio:
16.40
EPS:
7.2751
Net Cash Flow:
$12.36B
1W Performance:
-0.84%
1M Performance:
+3.01%
6M Performance:
+36.15%
1Y Performance:
+46.93%
1-Day Range:
$116.50
$119.56
1-Week Range:
$116.50
$122.19
52-Week Range:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
119.28 | 294.91B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
931.09 | 831.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.41 | 574.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.37 | 365.02B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.81 | 311.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors - finance.yahoo.com
Merck’s (NYSE:MRK) Terns Deal And S&P 500 Valuation Impact Explained - Kalkine Media
Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now? - Insider Monkey
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data ReviewMerck & Co (NYSE:MRK), Terns Ph - Benzinga
What's Going On With Merck Stock Tuesday? - Benzinga
Merck (MRK) Initiates Tender Offer for Terns Pharmaceuticals - GuruFocus
Strong Results Lifted Merck & Co (MRK) in Q4 - finance.yahoo.com
Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought? - 24/7 Wall St.
Merck (MRK) Collaborates in Promising Trial of Personalized Canc - GuruFocus
Merck's experimental HIV prevention pill could be made for less than $5 a year, researchers say - statnews.com
Merck begins tender offer to buy Terns Pharmaceuticals (MRK:NYSE) - Seeking Alpha
Merck begins tender offer to acquire Terns Pharmaceuticals, Inc. - marketscreener.com
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share - StreetInsider
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. - Business Wire
Terns rebuffed a higher bid before selling to Merck - finance.yahoo.com
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 - GlobeNewswire Inc.
Merck (NYSE: TERN) to acquire Terns for $53.00 per share cash - stocktitan.net
Merck to stop Gardasil production in Durham - MSN
Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Rathbones Group PLC - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Quilter Plc - MarketBeat
JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating - marketscreener.com
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Nvwm LLC Acquires 31,854 Shares of Merck & Co., Inc. $MRK - marketbeat.com
JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co - MarketBeat
Merck & Co., Inc. (MRK) stock price, news, quote and history - Yahoo Finance UK
Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK - MarketBeat
SS&H Financial Advisors Inc. Acquires 12,200 Shares of Merck & Co., Inc. $MRK - MarketBeat
SteelPeak Wealth LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Quintet Private Bank Europe S.A. - MarketBeat
Merck & Co., Inc. stock: Steady performer amid healthcare shifts - AD HOC NEWS
Erste Group Initiates Merck & Co(MRK.US) With Hold Rating - Moomoo
West Branch Capital LLC Sells 15,875 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock: Strong margins amid shifting pharma winds - ad-hoc-news.de
Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC - MarketBeat
16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Aberdeen Group plc - MarketBeat
Merck & Co., Inc. stock: A cornerstone of pharmaceutical innovation and dividend reliability for lon - AD HOC NEWS
FinancialContentMerck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer - markets.financialcontent.com
Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration - ROI-NJ
Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration - MarketScreener
Merck & Co Inc (MEX:MRK) Stock Price, Trades & News - GuruFocus
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investiga - PharmiWeb.com
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study - Insider Monkey
Merck's (MRK) Keytruda Gains Fast Track Status in Colorectal Can - gurufocus.com
Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co - MarketScreener
Merck wins EU nod for Keytruda combo in ovarian cancer (MRK) - seekingalpha.com
Merck (MRK) Gains EU Approval for Keytruda Regimen in Ovarian Ca - GuruFocus
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):